로딩 중…
지수 로딩 중…
Immunome, Inc.
IMNM· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$23.01+1.10%
2026-08-03
Financials
Valuation Metrics
Immunome, Inc.'s Market Cap is $2.61B. At end of 2025 it was $1.88B. Ranked #1881 of 3,112 in US market (top 60%), #692 of 1,445 on NASDAQ (top 48%), #112 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.61B | US#1,881/3,112 Sec#112/269 |
| Revenue | $4M | US#2,946/3,112 Sec#192/269 |
| Net Income | $-225M | US—/3,112 Sec—/269 |
| Total Assets | $620M | US#2,667/3,112 Sec#136/269 |
| Net Assets | $589M | US#2,131/3,112 Sec#95/269 |
| Value | ||
| P/B | 4.43x | US#2,065/3,112 Sec#127/269 |
| P/S | 649.04x | US#2,943/3,112 Sec#195/269 |
| FCF Yield | -7.89% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -38.15% | US#2,681/3,112 Sec#147/269 |
| ROA | -36.24% | US#2,910/3,112 Sec#181/269 |
| Op. Margin | -5947.90% | US#2,954/3,112 Sec#194/269 |
| Revenue Growth | -100.00% | US#2,948/3,112 Sec#190/269 |
| Financial Health | ||
| Debt Ratio | 5.28% | US#52/3,112 Sec#22/269 |
| Total Debt | $4M | US#2,876/3,112 Sec#225/269 |
| FCF | $-206M | US#2,737/3,112 Sec#218/269 |
| Cash | $583M | US#982/3,112 Sec#50/269 |
| Current Ratio | 21.68x | US#118/3,112 Sec#29/269 |
| Performance | ||
| 1Y Return | 117.28% | US#259/3,112 Sec#70/269 |
| 1M Return | -2.54% | US#1,972/3,112 Sec#101/269 |
| From 52W High | -16.78% | US#1,522/3,112 Sec#93/269 |
| 1Y MDD | -33.59% | US#1,612/3,112 Sec#104/269 |
| Trading | ||
| Volume | 1,752,107 shares | US#1,002/3,112 Sec#91/269 |
| Trading Value | $40M | US#1,523/3,112 Sec#100/269 |
| Per Share | ||
| EPS | $-2.43 | US—/3,112 Sec—/269 |
| BPS | $7.26 | US#2,011/3,112 Sec#98/269 |